We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rationally designed cyclic peptides and nanomaterials as 'next-generation' anti-amyloid therapeutics.
- Authors
Khairnar, Bhushan D.; Jha, Anjali; Rajwade, Jyutika M.
- Abstract
The pathological hallmark of many amyloid diseases is the aggregation and deposition of soluble proteins into toxic insoluble fibrils in various tissues. Without any definite cure for these proteinopathies, researchers have explored small molecules, antibodies, peptides, nanomaterials etc., as potential agents interacting with different conformational species of amyloid-forming proteins. Mainly, amyloid fibrillation inhibitors in the form of cyclic peptides (CPs) (based on amyloid and non-amyloid-forming protein sequences) show remarkable anti-amyloidogenic activity as well as chemical, thermal, and proteolytic stability over their linear counterparts. Furthermore, some 'add-on' attributes include ease of synthesis, amenability for chemical modification, precise and tight binding (high specificity) to target peptides, and biocompatibility. This article highlights the design, synthesis, bioactivity, and mechanistic evaluation of rationally designed CPs inhibitors against amyloid systems. This review also discusses the dual role of nanoparticles as inhibitors of amyloid fibrillation and as carriers for the delivery of therapeutic molecules across the blood–brain barrier. Thus, combining CPs and nanoparticles could represent 'next-generation therapeutics' for amyloid diseases.
- Subjects
CYCLIC peptides; SMALL molecules; AMYLOID beta-protein; NANOSTRUCTURED materials; BLOOD-brain barrier; AMINO acid sequence
- Publication
Journal of Materials Science, 2023, Vol 58, Issue 24, p9834
- ISSN
0022-2461
- Publication type
Article
- DOI
10.1007/s10853-023-08654-6